| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2018 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNLOGIC INC | 12 | Q3 2023 | 33.8% |
| AADI BIOSCIENCES INC | 9 | Q3 2023 | 37.2% |
| IDERA PHARMACEUTICALS INC | 9 | Q4 2022 | 2.4% |
| GENOCEA BIOSCIENCES INC | 8 | Q3 2022 | 32.1% |
| NABRIVA THERAPEUTICS PLC | 7 | Q2 2022 | 2.3% |
| CASTLE BIOSCIENCES INC | 6 | Q3 2023 | 77.2% |
| PULMONX CORP | 5 | Q4 2021 | 33.9% |
| AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 2.3% |
| ATEA PHARMACEUTICALS INC | 2 | Q2 2021 | 91.0% |
| ATEA PHARMACEUTICALS INC | 1 | Q1 2021 | 80.1% |
View ABG Innovation Capital Partners III GP Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View ABG Innovation Capital Partners III GP Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.